Physician profile
Maria Smith
NPI 1972804474
$4,210.78
in general payments reported to CMS, 2019-2025
21 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $217 · 2023: $991 · 2024: $1,559 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,966 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,966.03 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.16 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $487.60 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $386.56 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $332.07 | 2023-2025 | Auvelity |
| Lundbeck LLC | $300.29 | 2022-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $274.44 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $259.64 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $240.11 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $227.35 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $218.15 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Ironshore Pharmaceuticals INC. | $176.25 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $168.73 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.75 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $129.24 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $89.48 | 2022-2024 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $77.61 | 2023 | Invega Sustenna, Invega Trinza, Invega |
| Collegium Pharmaceutical, INC. | $62.60 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.52 | 2025 | |
| Progenics Pharmaceuticals, INC. | $25.00 | 2022 | |
| Indivior INC. | $16.91 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $13.32 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.